• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

    5.215 +0.065 (+1.26%)
    Delayed Quote Updated: 12:26 PM EST, Nov 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 203,392
    Open 5.160
    Bid (Size) 5.210 (100)
    Ask (Size) 5.220 (500)
    Prev. Close 5.150
    Today's Range 5.160 - 5.390
    52wk Range 4.960 - 20.56
    Shares Outstanding 17,151,024
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints George Lederman as Executive Vice President of Strategy and Transformation
    Via Investor Brand Network
    Topics Artificial Intelligence
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 3 Data Showing TONMYA(R) Improves Fibromyalgia Symptoms and Physical Function
    Via Investor Brand Network

    Performance

    52-Week Range 74.6% below 52-week high
    5.215
    4.9652W Low 20.5652W High
    1 Week 5.4% below 1-week high
    4.961W Low 5.511W High

    Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) traded between $4.96 and $20.56 over the past 52 weeks and last traded at $5.21, 74.6% below its 52-week high. Over the past week it ranged between $4.96 and $5.51.

    Past 12 Months
    -3.2%
    -35.4%
    -51.1%
    -60.0%
    -68.5%
    -72.2%
    1W -$0.17
    1M -$2.86
    3M -$5.45
    6M -$7.81
    YTD -$11.34
    1Y -$13.54

    TNXP was -72.2% over the past year, -60.0% over six months, -68.5% year to date, -3.2% in the last week.

    12 Months vs Market
    TNXP
    -72.2%
    DIA
    +9.1%
    SPY
    +10.5%
    QQQ
    +8.7%
    IWM
    +14.4%

    Over the past 12 months TNXP returned -72.2% versus DIA (Dow) +9.1%, SPY (S&P 500) +10.5%, QQQ (Nasdaq 100) +8.7% and IWM (Russell 2000) +14.4%.

    Volume & Liquidity 0.31× 3-mo avg
    Today 203,392 3-mo avg 656.5K
    1W
    667.2K
    1M
    1.0M
    3M
    656.5K
    6M
    594.0K
    YTD
    520.8K
    1Y
    545.2K

    TNXP most recently traded 203,392 shares against a 3-month average daily volume of 656.5K.

    More News

    Read More
    NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Report Third-Quarter 2026 Financial Results Nov. 9
    Via Investor Brand Network
    TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present TONMYA(R) Fibromyalgia Data at 2026 World Congress on Pain
    Via Investor Brand Network
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present TNX-801 Vaccine Platform at World Vaccine Congress Europe
    Via Investor Brand Network
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA(R) Medicare Coverage to 32 Million Lives
    Via Investor Brand Network
    News headline image
    Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears ↗
    Via MarketBeat
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Thomas Englese to Chief Commercial Officer
    Via Investor Brand Network
    NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Cantor 2026 Global Healthcare Conference
    Via Investor Brand Network
    News headline image
    Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline ↗
    Via MarketBeat
    News headline image
    Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Tonix Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
    Via Investor Brand Network
    NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
    Via Investor Brand Network
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in August, September Investor Conferences
    Via Investor Brand Network
    TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives FDA Feedback for Lyme Disease Prevention Study
    Via Investor Brand Network
    MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Schedules Second-Quarter 2026 Results Call for Aug. 10
    Via Investor Brand Network
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Mpox Research Supporting TNX-801 Vaccine Development
    Via Investor Brand Network
    BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives
    Via Investor Brand Network
    NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Enrolls First Patient in Phase 2 Depression Trial
    Via Investor Brand Network
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in BTIG Infectious Disease Day 2026
    Via Investor Brand Network
    MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Coverage to 52 Million Commercial Lives
    Via Investor Brand Network
    TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Data Highlighting Widespread Opioid Use Among Fibromyalgia Patients
    Via Investor Brand Network
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Phase 1 TNX-1500 Data Supporting Advancement into Phase 2
    Via Investor Brand Network
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Fibromyalgia Burden Data at ISPOR 2026
    Via Investor Brand Network

    Frequently Asked Questions

    Is Tonix Pharmaceuticals Holding Corp. - Common Stock publicly traded?
    Yes, Tonix Pharmaceuticals Holding Corp. - Common Stock is publicly traded.
    What exchange does Tonix Pharmaceuticals Holding Corp. - Common Stock trade on?
    Tonix Pharmaceuticals Holding Corp. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tonix Pharmaceuticals Holding Corp. - Common Stock?
    The ticker symbol for Tonix Pharmaceuticals Holding Corp. - Common Stock is TNXP on the Nasdaq Stock Market
    What is the current price of Tonix Pharmaceuticals Holding Corp. - Common Stock?
    The current price of Tonix Pharmaceuticals Holding Corp. - Common Stock is 5.215
    When was Tonix Pharmaceuticals Holding Corp. - Common Stock last traded?
    The last trade of Tonix Pharmaceuticals Holding Corp. - Common Stock was at 11/03/26 12:26 PM ET
    What is the market capitalization of Tonix Pharmaceuticals Holding Corp. - Common Stock?
    The market capitalization of Tonix Pharmaceuticals Holding Corp. - Common Stock is 89.44M
    How many shares of Tonix Pharmaceuticals Holding Corp. - Common Stock are outstanding?
    Tonix Pharmaceuticals Holding Corp. - Common Stock has 89M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.